635702-31-7

Usage

Uses

Used in Pharmaceutical Industry:
4-BROMO-2-FLUORO-N-HYDROXYBENZAMIDINE is used as an intermediate in the synthesis of pharmaceuticals for its potential role in the development of new drug candidates. Its unique structure, including the bromine and fluorine atoms, may contribute to the creation of novel therapeutic agents.
Used in Agrochemical Industry:
4-BROMO-2-FLUORO-N-HYDROXYBENZAMIDINE is used as an intermediate in the synthesis of agrochemicals, where it may contribute to the development of new pesticides or other agricultural products. Its chemical properties could be beneficial in enhancing the effectiveness of these compounds.
Used in Organic Chemistry:
4-BROMO-2-FLUORO-N-HYDROXYBENZAMIDINE is used as a building block in the production of various organic compounds. Its presence in the synthesis process can lead to the creation of new molecules with specific properties, useful in different chemical applications.
Used in Chemical Reactions:
4-BROMO-2-FLUORO-N-HYDROXYBENZAMIDINE may have properties that could be beneficial in certain chemical reactions, such as acting as a catalyst or participating in specific binding processes. Its unique structure allows it to potentially influence the outcomes of various chemical processes.

InChI:InChI=1/C7H6BrFN2O/c8-4-1-2-5(6(9)3-4)7(10)11-12/h1-3,12H,(H2,10,11)

Upstream product

• 105942-08-3 4-bromo-6-fluorobenzonitrile 

Downstream Products

• 749927-78-4 3-(4-Bromo-2-fluoro-phenyl)-5-methyl-[1,2,4]oxadiazole 
• 1323995-08-9 tert-butyl 4-(3-(4-bromo-2-fluorophenyl)-1,2,4-oxadiazol-5-yl)phenylcarbamate 
• 1557037-73-6 3-(4-bromo-2-fluoro-phenyl)-[1,2,4]oxadiazole-5-carboxylic acid ethyl ester 
• 1557037-75-8 3-(4-bromo-2-fluoro-phenyl)-[1,2,4]oxadiazole-5-carboxylic acid 
• 1282516-76-0 5-(2-(4-bromo-2-fluorophenyl)-1H-imidazol-4-yl)-1-isopropyl-3-methyl-1H-1,2,4-triazole 
• 1282516-77-1 2-(2-(4-bromo-2-fluorophenyl)-4-(1-isopropyl-3-methyl-1H-1,2,4-triazol-5-yl)-1H-imidazol-1-yl)ethanol 
• 1282514-64-0 ethyl 2-(4-(2-(1-isopropyl-3-methyl-1H-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)-1H-pyrazol-1-yl)-2-methylpropanoate 
• 1282513-03-4 2-(4-(2-(1-isopropyl-3-methyl-1H-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)-1H-pyrazol-1-yl)-2-methylpropanoic acid 
• 1282512-48-4 taselisib 
• 1282516-74-8 9-bromo-5,6-dihydrobenzo[f]imidazo[1,2-d]-[1,4]oxazepine-2-carboxylic acid 
• 1028344-65-1 C₁₂H₁₀BrFN₂O₃ 

Relevant academic research and scientific papers

PHENYLALANINE DERIVATIVES AND THEIR USE AS NON-PEPTIDE GLP-1 RECEPTOR MODULATORS

Provided herein are non-peptide GLP-1 receptor modulator compounds, for example, of Formula I, pharmaceutical compositions comprising such compounds, and processes of preparation thereof. Also provided are methods of their use for the treatment of a metab

BRIDGED BICYCLIC PIPERIDINE DERIVATIVES AND METHODS OF USE THEREOF

The present invention relates to Bridged Bicyclic Piperidine Derivatives, compositions comprising a Bridged Bicyclic Piperidine Derivative, and methods of using the Bridged Bicyclic Piperidine Derivatives for treating or preventing obesity, diabetes, a me

Acetic acid aldose reductase inhibitors bearing a five-membered heterocyclic core with potent topical activity in a visual impairment rat model

A number of 1,2,4-oxadiazol-5-yl-acetic acids and oxazol-4-yl-acetic acids were synthesized and tested for their ability to inhibit aldose reductase (ALR2). The oxadiazole derivatives, 7c, 7f, 7i, and 8h, 8i, proved to be the most active compounds, exhibiting inhibitory levels in the submicromolar range. In this series, the phenyl group turned out to be the preferred substitution pattern, as its lengthening to a benzyl moiety determined a general reduction of the inhibitory potency. The lead compound, 2-[3-(4-methoxyphenyl)-1,2,4- oxadiazol-5-yl]acetic acid, 7c, showed an excellent in vivo activity, proving to prevent cataract development in severely galactosemic rats when administered as an eye-drop solution in the precorneal region of the animals. Computational studies on the ALR2 inhibitors were performed to rationalize the structure-activity relationships observed and to provide the basis for further structure-guided design of novel ALR2 inhibitors.